Determining the effect of care methods on preventing of prediabetes (IGT) to type 2 diabetes

Investigating methods to prevent the conversion of prediabetes (IGT) to type 2 diabetes : a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241016063389N1

Enrollment

300

Registered

2024-11-02

Start date

2024-11-15

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: The drug used in the intervention group is metformin 500 mg three times a day from Pharmachemy for three months. Intervention 2: Intervention group: this group rec

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age: 20 years and older , up to 70 y/o Impaired glucose tolerance test according to WH0 criteria (plasma glucose concentration 2 hours after eating 75 gr. of oral glucose between 140-199 mg/dL) BMI: greater than or equal to 24 mg/dL

Exclusion criteria

Exclusion criteria: Diagnosed and confirmed diabetes Fasting plasma glucose higher than 126 mg/dL Dissatisfaction or Lack of consent to participate in the study pulmonary disease or dependence on oxygen or daily bronchodilators Renal disease or higher creatinine equal to 1.4 mg/dL in men and 1.3 mg/dL in women Liver disease such as hepatitis and cirrhosis Active cancer Mental conditions that limit life expectancy and increase risk with intervention.

Design outcomes

Primary

Measure	Time frame
The percentage of patients recovered from the pre-diabetes stage. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: Laboratory Test (Fasting Blood Sugar,A hemoglobin A1C, 2-Hour Post Prandial Blood Glucose).	—

Secondary

Measure	Time frame
Lipid profile. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: Laboratory test Data.;Insulin plasma level. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: Laboratory test Data.;Maximum amount of oxygen. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: ErgoSpirometry.;Blood Pressure. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: blood pressure measurement device.	—

Measure

Time frame

Lipid profile. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: Laboratory test Data.;Insulin plasma level. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: Laboratory test Data.;Maximum amount of oxygen. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: ErgoSpirometry.;Blood Pressure. Timepoint: before the start of the intervention and 3, 6, 9, and 12 months after the start of the study. Method of measurement: blood pressure measurement device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Saberian

Shahid Beheshti University of Medical Sciences

farnaz.saberian@gmail.com+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026